While the positive control HER2 kinase inhibitor lapatinib was more effective than JBS2 at reducing tumor volume, it is noteworthy that co-treatment with lapatinib+JBS2 significantly shortened the time for lapatinib to reach its maximal effect, from 2 weeks to 1 week (Figure 4A, * p = 0.026 comparing JBS2+lapatinib versus lapatinib alone after 1-week treatment). Here, ERBB2 is linked to neoplasm.